Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women
- PMID: 39228502
- PMCID: PMC11366988
- DOI: 10.31083/j.rcm2508308
Advantages of using Genetically Elevated Lipoprotein(a) Levels in Predicting 5-Year Major Adverse Cardiovascular Events Relating to Coronary Artery Disease in Women
Abstract
Background: This study aimed to investigate major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) over 5 years, in general, and depending on sex, lipoprotein(a) level, and number of kringle IV type 2 (KIV-2) repeats in the Lipoprotein(A) (LPA) gene.
Methods: This study comprised 216 patients (120 women and 96 men) hospitalized with a diagnosis of "CAD, unstable angina IIB class". The three-point risk of MACEs was assessed over 5 years: cardiovascular death, non-fatal myocardial infarction, and stroke. The number of KIV-2 repeats in the LPA gene was determined by quantitative real-time polymerase chain reaction (qPCR).
Results: The relative risk of MACE in patients with elevated lipoprotein(a) (Lp(a)) was 2.0 (95% CI 1.04-3.87, p 0.05) for quartile 4 (Q4) 48 mg/dL versus quartile 1 (Q1) 6 mg/dL. This was mainly attributable to an increase in men-relative risk (RR) 2.6 (95% CI 1.10-6.16, p 0.05)-but not in women: RR 1.4 (95% CI 0.50-3.92). Mean lipoprotein(a) levels were inversely correlated with 42.5 and 7.5 for Q1 and Q4 KIV-2 repeat numbers, respectively. The relative risks of MACE for Q1 vs. Q4 KIV-2 repeats were as follows: 3.0 (95% CI 1.48-6.08, p 0.001) for all patients; 3.0 (95% CI 1.20-6.55, p 0.01) for men; 3.3 (95% CI 1.02-10.4, p 0.05) for women.
Conclusions: Quantifying kringle IV type 2 repeat copy number in the LPA gene using qPCR more accurately reflects the risk of major adverse cardiovascular events within 5 years in women with coronary artery disease.
Keywords: CAD; LPA kringle IV type 2 genetic polymorphism; MACE; lipoprotein(a); qPCR; sex differences.
Copyright: © 2024 The Author(s). Published by IMR Press.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine . 2013;273:6–30. - PubMed
-
- Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Circulation . 2014;129:635–642. - PMC - PubMed
-
- Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA . 2009;301:2331–2339. - PubMed
-
- Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. European Heart Journal . 2019;40:2760–2770. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
